# Palisade Bio, Inc.: overview PALI · Nasdaq · CIK 1357459 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pali.md) · [Financials](/companies/pali/financials.md) · [Filings](/companies/pali/filings.md) · [Insiders](/companies/pali/insiders.md) Latest reported revenue: [$500.0k](/filings/0001357459-26-000016.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001357459-26-000016). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0000950170-24-124664.md) | [0.0 d](/filings/0000950170-25-043859.md) | [0.0](/filings/0001357459-26-000010.md) | [0.0](/filings/0001357459-26-000016.md) | [0.0](/filings/0001193125-25-274262.md) | [0.0 d](/filings/0001357459-26-000004.md) | [0.0](/filings/0001357459-26-000010.md) | [500](/filings/0001357459-26-000016.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(2339.6%)](/filings/0001357459-26-000016.md) | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(2114.8%)](/filings/0001357459-26-000016.md) | | Diluted EPS | $ per share | [(2.32)](/filings/0001193125-25-274262.md) | not reported | [(0.47)](/filings/0001357459-26-000010.md) | [(0.58)](/filings/0001357459-26-000016.md) | [(0.38)](/filings/0001193125-25-274262.md) | not reported | [(0.05)](/filings/0001357459-26-000010.md) | [(0.05)](/filings/0001357459-26-000016.md) | | Free cash flow | $k | [(3,133) d](/filings/0001193125-25-274262.md) | [(2,381) d](/filings/0001357459-26-000004.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [0.0](/filings/0000950170-24-036402.md) | [0.3](/filings/0000950170-25-043859.md) | [0.0](/filings/0000950170-25-043859.md) | [0.0](/filings/0001357459-26-000004.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(5228.0%)](/filings/0000950170-25-043859.md) | not reported | not reported | | Net margin | % | not reported | not reported | [(4920.0%)](/filings/0000950170-25-043859.md) | not reported | not reported | | Diluted EPS | $ per share | [(169.74)](/filings/0000950170-23-009226.md) | [(16.53)](/filings/0000950170-24-036402.md) | [(27.01)](/filings/0000950170-25-043859.md) | [(10.19)](/filings/0001357459-26-000004.md) | [(0.30)](/filings/0001357459-26-000004.md) | | Free cash flow | $m | [(14.8)](/filings/0000950170-23-009226.md) | [(13.4)](/filings/0000950170-24-036402.md) | [(11.1)](/filings/0000950170-25-043859.md) | [(12.2)](/filings/0001357459-26-000004.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pali/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $27.3m | 13,063,687 | | New +13,063,687 | | [B Group, Inc.](/funds/2043476.md) | 2026-06-30 | $23.9m | 11,414,285 | | Unchanged | | [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $23.2m | 11,081,434 | | Added +2,370,049 | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $22.4m | 10,689,452 | | Not compared | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $21.8m | 10,436,760 | | Added +8,560,420 | | [Octagon Capital Advisors LP](/funds/1839435.md) | 2026-06-30 | $21.5m | 10,276,317 | | Unchanged | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $18.8m | 10,689,452 | | Not compared | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $17.6m | 8,425,065 | | Reduced −503,084 | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $14.9m | 7,124,116 | | Unchanged | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $12.1m | 5,785,189 | | Unchanged | ## Recent filings [All 1,139 filings](/companies/pali/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-10 | 20:18 ET | [8-K](/filings/0001357459-26-000017.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001357459-26-000017 | | 2026-08-10 | 20:06 ET | [10-Q](/filings/0001357459-26-000016.md) | Quarterly report, period 2026-06-30 | 0001357459-26-000016 | | 2026-06-11 | 21:23 ET | [8-K](/filings/0001493152-26-028322.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-028322 | | 2026-05-12 | 20:14 ET | [8-K](/filings/0001357459-26-000011.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001357459-26-000011 | | 2026-05-12 | 20:04 ET | [10-Q](/filings/0001357459-26-000010.md) | Quarterly report, period 2026-03-31 | 0001357459-26-000010 | | 2026-04-29 | 20:49 ET | [DEF 14A](/filings/0001493152-26-019629.md) | Proxy statement, period 2026-04-29 | 0001493152-26-019629 | | 2026-04-02 | 12:34 ET | [8-K](/filings/0001493152-26-014822.md) | 8.01 Other events | 0001493152-26-014822 | | 2026-03-20 | 20:22 ET | [10-K](/filings/0001357459-26-000004.md) | Annual report, period 2025-12-31 | 0001357459-26-000004 | | 2025-12-04 | 21:40 ET | [8-K](/filings/0001493152-25-026195.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-25-026195 | | 2025-11-10 | 21:14 ET | [10-Q](/filings/0001193125-25-274262.md) | Quarterly report, period 2025-09-30 | 0001193125-25-274262 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001357459-26-000004.md), filed Mar 20, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e289d7d8-a344-4ebb-a4f8-949796961ab7) ## About the filer - CIK: 1357459 - Tickers: PALI - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.